Prognostic contributions of the underlying inflammatory disease and acute organ dysfunction in critically ill patients with systemic rheumatic diseases

被引:32
作者
Faguer, Stanislas
Ciroldi, Magali
Mariotte, Eric
Galicier, Lionel
Rybojad, Michel
Canet, Emmanuel
Bengoufa, Djaouida
Schlemmer, Benoit
Azoulay, Elie [1 ,2 ]
机构
[1] Hop St Louis, AP HP, Med ICU, F-75010 Paris, France
[2] Univ Paris 07, UFR Med, F-75010 Paris, France
关键词
Inflammation; ARDS; Shock; Immunocompromised patients; Steroids; INTENSIVE-CARE-UNIT; LUPUS-ERYTHEMATOSUS; ACUTE PHYSIOLOGY; VASCULITIS; MORTALITY;
D O I
10.1016/j.ejim.2012.11.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Knowledge about the clinical features, outcomes and predictors of short-term mortality in critically ill patients with systemic rheumatic disease (SRD) requires further characterization. Methods: Single center retrospective observational cohort study of 149 critically ill patients with SRD followed in a French medical intensive care unit over a 20-year period. Multivariate logistic regression was used to identify predictors of day-30 mortality. Results: Most patients (63%) had systemic lupus erythematosus, rheumatoid arthritis, or systemic sclerosis. The critical illness usually developed late after the diagnosis of SRD (median time to ICU admission 82 months, IQR [9-175] in the 127 patients with a previous diagnosis of SRD). Two-thirds of patients were taking immunosuppressive drugs to treat their SRD. Reasons for ICU admission were infection (47%), SRD exacerbation (48%), and iatrogenic complications (11%); the most common organ failure was acute renal failure. Thirty-day mortality was 16%. Predictors of 30-day mortality were the LODS score on day 1 (OR 1.3 (1.06-1.48)), bacterial pneumonia (OR 3.8 (1.03-14.25)), need for vasoactive drugs (OR 7.1 (1.83-27.68)), SRD exacerbation (OR 4.3 (1.15-16.53)), and dermatomyositis (OR 9.2 (1.05-80.78)) as the underlying disease. Year of ICU admission was not significantly associated with 30-day survival. Conclusion: Patients with SRD are mostly admitted in the ICU with infection or SRD exacerbation, and can be treated with immunosuppressive therapy and life-sustaining interventions with acceptable 30-day mortality. Death is associated with both the severity of the acute medical condition and the characteristics of the underlying SRD. (C) 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:E40 / E44
页数:5
相关论文
共 27 条
[1]   Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients [J].
Afessa, B ;
Tefferi, A ;
Litzow, MR ;
Krowka, MJ ;
Wylam, ME ;
Peters, SG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (05) :641-645
[2]  
[Anonymous], 2000, N ENGL J MED, V342, P1301
[3]   Study of critically ill patients with systemic lupus erythematosus [J].
Ansell, SM ;
Bedhesi, S ;
Ruff, B ;
Mahomed, AG ;
Richards, G ;
Mer, M ;
Feldman, C .
CRITICAL CARE MEDICINE, 1996, 24 (06) :981-984
[4]  
Anthony Fauci.S., 2008, HARRISONS PRINCIPLES
[5]   Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria [J].
Bellomo, Rinaldo ;
Kellum, John A. ;
Ronco, Claudio .
INTENSIVE CARE MEDICINE, 2007, 33 (03) :409-413
[6]   Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome - A retrospective analysis of causes and factors predictive of mortality based on 595 patients [J].
Bourgarit, A ;
Le Toumelin, P ;
Pagnoux, C ;
Cohen, P ;
Mahr, AF ;
Le Guern, VR ;
Mouthon, L ;
Guillevin, L .
MEDICINE, 2005, 84 (05) :323-330
[7]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[8]   Advances in the use of biologic agents for the treatment of systemic vasculitis [J].
Chung, Sharon A. ;
Seo, Philip .
CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (01) :3-9
[9]   Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit [J].
Cruz, BA ;
Ramanoelina, J ;
Mahr, A ;
Cohen, P ;
Mouthon, L ;
Cohen, Y ;
Hoang, P ;
Guillevin, L .
RHEUMATOLOGY, 2003, 42 (10) :1183-1188
[10]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140